share_log

EXCLUSIVE: Pasithea Therapeutics Announces Results Of Preclinical Study Demonstrating Tolerizing Vaccine Efficacy In Relapsing-Remitting Model Multiple Sclerosis

Benzinga Real-time News ·  Aug 11, 2022 07:30
EXCLUSIVE: Pasithea Therapeutics Announces Results Of Preclinical Study Demonstrating Tolerizing Vaccine Efficacy In Relapsing-Remitting Model Multiple Sclerosis
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment